OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
Vikas S. Sridhar, Habib Rahman, David Z.I. Cherney
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. S1, pp. 55-68
Open Access | Times Cited: 22
Vikas S. Sridhar, Habib Rahman, David Z.I. Cherney
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. S1, pp. 55-68
Open Access | Times Cited: 22
Showing 22 citing articles:
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, et al.
Kidney International (2021) Vol. 100, Iss. 1, pp. 215-224
Open Access | Times Cited: 280
David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, et al.
Kidney International (2021) Vol. 100, Iss. 1, pp. 215-224
Open Access | Times Cited: 280
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
Pardeep S. Jhund, Scott D. Solomon, Kieran F. Docherty, et al.
Circulation (2020) Vol. 143, Iss. 4, pp. 298-309
Open Access | Times Cited: 244
Pardeep S. Jhund, Scott D. Solomon, Kieran F. Docherty, et al.
Circulation (2020) Vol. 143, Iss. 4, pp. 298-309
Open Access | Times Cited: 244
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
Vennela Avula, Garima Sharma, Mikhail Kosiborod, et al.
JACC Heart Failure (2023) Vol. 12, Iss. 1, pp. 67-78
Open Access | Times Cited: 43
Vennela Avula, Garima Sharma, Mikhail Kosiborod, et al.
JACC Heart Failure (2023) Vol. 12, Iss. 1, pp. 67-78
Open Access | Times Cited: 43
SGLT2 Inhibitors: The Sweet Success for Kidneys
Atit Dharia, Abid Ali Khan, Vikas S. Sridhar, et al.
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 369-384
Open Access | Times Cited: 30
Atit Dharia, Abid Ali Khan, Vikas S. Sridhar, et al.
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 369-384
Open Access | Times Cited: 30
Caffeic Acid, One of the Major Phenolic Acids of the Medicinal Plant Antirhea borbonica, Reduces Renal Tubulointerstitial Fibrosis
Bryan Veeren, Matthieu Bringart, Chloé Turpin, et al.
Biomedicines (2021) Vol. 9, Iss. 4, pp. 358-358
Open Access | Times Cited: 43
Bryan Veeren, Matthieu Bringart, Chloé Turpin, et al.
Biomedicines (2021) Vol. 9, Iss. 4, pp. 358-358
Open Access | Times Cited: 43
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
David Z.I. Cherney, Jacob A. Udell, Daniel J. Drucker
Med (2021) Vol. 2, Iss. 11, pp. 1203-1230
Open Access | Times Cited: 36
David Z.I. Cherney, Jacob A. Udell, Daniel J. Drucker
Med (2021) Vol. 2, Iss. 11, pp. 1203-1230
Open Access | Times Cited: 36
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
Davide Margonato, Giuseppe Galati, Simone Mazzetti, et al.
Heart Failure Reviews (2020) Vol. 26, Iss. 2, pp. 337-345
Open Access | Times Cited: 39
Davide Margonato, Giuseppe Galati, Simone Mazzetti, et al.
Heart Failure Reviews (2020) Vol. 26, Iss. 2, pp. 337-345
Open Access | Times Cited: 39
Risk of diabetic macular oedema with sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes patients: A multi‐institutional cohort study in Taiwan
Yu‐Chen Su, Shih‐Chieh Shao, Edward Chia‐Cheng Lai, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 9, pp. 2067-2076
Closed Access | Times Cited: 32
Yu‐Chen Su, Shih‐Chieh Shao, Edward Chia‐Cheng Lai, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 9, pp. 2067-2076
Closed Access | Times Cited: 32
Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
Xiang Zhou, Xiaofei Ye, Xiaojing Guo, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 32
Xiang Zhou, Xiaofei Ye, Xiaojing Guo, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 32
Association Between SGLT2 Inhibitors vs DPP4 Inhibitors and Renal Outcomes Among Patients With Type 2 Diabetes
Philip Chun-Ming Au, K. C. B. Tan, Bernard M.Y. Cheung, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 7, pp. e2962-e2970
Open Access | Times Cited: 17
Philip Chun-Ming Au, K. C. B. Tan, Bernard M.Y. Cheung, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 7, pp. e2962-e2970
Open Access | Times Cited: 17
A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?
Fabrice Bonnet, Mark E. Cooper, Laetitia Koppe, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S6, pp. 55-65
Open Access | Times Cited: 2
Fabrice Bonnet, Mark E. Cooper, Laetitia Koppe, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S6, pp. 55-65
Open Access | Times Cited: 2
Evaluation of Pharmacokinetic Interactions Between the New SGLT2 Inhibitor SHR3824 and Valsartan in Healthy Chinese Volunteers
Yunzhe Huang, Ran Liu, Yaqin Wang, et al.
Clinical Therapeutics (2022) Vol. 44, Iss. 7, pp. 945-956
Closed Access | Times Cited: 11
Yunzhe Huang, Ran Liu, Yaqin Wang, et al.
Clinical Therapeutics (2022) Vol. 44, Iss. 7, pp. 945-956
Closed Access | Times Cited: 11
Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 10, pp. 100135-100135
Open Access | Times Cited: 6
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 10, pp. 100135-100135
Open Access | Times Cited: 6
Cardiorenal Protection in Diabetic Kidney Disease
Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, et al.
Endocrinology and Metabolism (2021) Vol. 36, Iss. 2, pp. 256-269
Open Access | Times Cited: 13
Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, et al.
Endocrinology and Metabolism (2021) Vol. 36, Iss. 2, pp. 256-269
Open Access | Times Cited: 13
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials
Vikas S. Sridhar, Brendon L. Neuen, Robert A. Fletcher, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2331-2339
Open Access | Times Cited: 5
Vikas S. Sridhar, Brendon L. Neuen, Robert A. Fletcher, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2331-2339
Open Access | Times Cited: 5
Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes
Ai‐Yu Yang, Hung‐Chun Chen
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 6
Ai‐Yu Yang, Hung‐Chun Chen
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 6
Sodium–Glucose Cotransporter-2 Inhibitors Could Help Delay Renal Impairment in Patients with Type 2 Diabetes: A Real-World Clinical Setting
Gyunam Park, Byung-Ha Choi, Soyoung Kang, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 18, pp. 5259-5259
Open Access | Times Cited: 5
Gyunam Park, Byung-Ha Choi, Soyoung Kang, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 18, pp. 5259-5259
Open Access | Times Cited: 5
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the NordicEMPRISE study
Thomas Nyström, Emilie Toresson Grip, Joel Gunnarsson, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 261-271
Open Access | Times Cited: 4
Thomas Nyström, Emilie Toresson Grip, Joel Gunnarsson, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 261-271
Open Access | Times Cited: 4
Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes
Sohee Park, Han Eol Jeong, Sungho Bea, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3248-3258
Open Access | Times Cited: 2
Sohee Park, Han Eol Jeong, Sungho Bea, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3248-3258
Open Access | Times Cited: 2
Cardiovascular benefits beyond urinary glucose excretion: A hypothesis generated from two meta‐analyses
Chu Lin, Xiaoling Cai, Linong Ji
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 550-554
Closed Access | Times Cited: 4
Chu Lin, Xiaoling Cai, Linong Ji
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 550-554
Closed Access | Times Cited: 4
SGLT2 and GLP - 1 Inhibitors: Enlightening their Role beyond their Glucose Lowering Properties
Geetanjali Mehra
International Journal of Science and Research (IJSR) (2024) Vol. 13, Iss. 4, pp. 709-714
Open Access
Geetanjali Mehra
International Journal of Science and Research (IJSR) (2024) Vol. 13, Iss. 4, pp. 709-714
Open Access
Real-Life Individual Comparison of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure and Diabetes Mellitus
Mehmet Birhan Yılmaz, Ahmet Çelik, Tuğçe Çöllüoğlu, et al.
American Journal of Cardiovascular Drugs (2024)
Closed Access
Mehmet Birhan Yılmaz, Ahmet Çelik, Tuğçe Çöllüoğlu, et al.
American Journal of Cardiovascular Drugs (2024)
Closed Access
